Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
PF-4708671
Cat. No.:
OB0225LY-0311
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
PF-4708671 is a specific GSK-3 inhibitor widely used in various cell signaling pathway studies.
Synonym:
PF4708671; 1255517-76-0; 2-((4-(5-Ethylpyrimidin-4-yl)piperazin-1-yl)methyl)-5-(trifluoromethyl)-1H-benzo[d]imidazole; 2-[[4-(5-Ethylpyrimidin-4-yl)piperazin-1-yl]methyl]-6-(trifluoromethyl)-1H-benzimidazole; 2-[[4-(5-Ethylpyrimidin-4-yl)piperazin-1-yl]methyl]-5-(trifluoromethyl)-1H-benzo[d]imidazole
CAS No.:
1255517-76-0
Compound CID:
51371303
Formula:
C19H21F3N6
Formula Weight:
390.41
Specification
Relative Density:
1.348 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
PF-4708671 can be used to study signaling pathways related to glycogen metabolism and neurodegenerative diseases.
Library Information
Targets:
S6 Kinase
Receptors:
Autophagy; p70 S6K; Ribosomal S6 Kinase (RSK)
Pathways:
MAPK; Autophagy; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-5
Plate Location:
a4
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
19.5 mg/mL; 50 mM
Ethanol Max Solubility:
19.5 mg/mL; 50 mM
ALogP:
3.886
HBA_Count:
3
HBD_Count:
1
Rotatable Bond:
5
